12,372 trials
Known or Suspected Focal Liver Lesions · Severe Renal Impairment
Primary: Co-primary Endpoint: Lesion Border Delineation in Combined MRI Compared to Unenhanced MRI — 2.51; 3.46; 3.00; 3.80 score on a scale — p=<0.001
Carcinoma, Nonsquamous Non-small-cell Lung
Primary: Progression-free Survival (PFS) — 7.1; 8.3 Months — p=0.8721
Heart Diseases
Primary: Effectiveness of Beta-blocker Therapy Reducing Post-operative Myocardial Injury — 9; 11 participants
PTSD
Primary: Incidence of Newly Emergent Adverse Events — 26; 19 Participants
Magnesium Sulfate - PPHN
Primary: Mean Airway Pressure (cm H2O) — 14.1; 13.8; 13.7; 13.25 (cm H2O) — p=0.83
HIV · Smoking Cessation
Primary: 7-day Abstinence — 4; 17; 15; 29 Participants
Hip Fracture · Frailty · Sarcopenia
Primary: Change in Six Minute Walk Distance — 42.69; 40.50; 37.65; 42.38 Meters — p=0.853
Respiratory Syncytial Virus Infection
Primary: RSV Season 1: Number of Participants With Respiratory Syncytial Virus (RSV)-Associated Medically Attended Lower Respiratory Infection (MALRI) — 60; 74 Participants…
Anemia · Iron Deficiency Anemia
Primary: Feasibility of Enrolling Patients in the Trial — 85 participants
Transthyretin (TTR) Amyloid Cardiomyopathy
Primary: Time to All-Cause Mortality: Cohort A — 58.7; 35.8 Months — p=0.0001
Meningococcal Immunization · Healthy Volunteers
Primary: Group 5 + 7 and Group 6 + 8: Percentage of Participants Who Achieved Antibody Titers ≥1:8 Against Meningococcal Serogroups A, C, Y, and W — 89.6; 83.1; 99.3; 77.7…
ALS
Primary: Number of Patients With AEs and Adverse Drug Reactions — 6; 0 Participants
Sarcopenia · Geriatric · Muscle Mass
Primary: IGF-1 Levels — 78.92; 77.08 ng/dl
Recurrent or Metastatic Nasopharyngeal Cancer
Primary: Progression-free Survival as Assessed by the Independent Review Committee (IRC) — 9.2; 7.4 Months
Stroke, Acute
Primary: Number of Participants With Return to Baseline Neurological Functioning Measured by the Modified Rankin Scale (mRS) — 309; 338 Participants